CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially those with relapsed disease. While CAR-T products provide many benefits, it is also important to better understand the impact of these therapies on quality of life (QoL), including adverse events such as cytokine release syndrome (CRS) and neurotoxicity.

In this exclusive podcast, Kedar Kirtane, MD, Laura Oswald, PhD, and Heather Jim, PhD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discuss the importance of investigating patient-reported outcomes in CAR-T recipients. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) meeting held in Tampa, FL.